Published • loading... • Updated
Ona Therapeutics Secures $86.6 Million for Two ADCs Against Therapy-Resistant Cancers
Summary by bionity.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ona Therapeutics, a global biopharmaceutical company pioneering the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of therapy-resistant cancers, announced the closing of an oversubscribed Series B financing round in H...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
